Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03801668

Recruitment Status : Unknown

Verified January 2022 by Xianglin Yuan, Huazhong University of Science and Technology.
Recruitment status was: Recruiting

First Posted : January 11, 2019

Last Update Posted : January 4, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Information provided by (Responsible Party):

Xianglin Yuan, Huazhong University of Science and Technology

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	December 31, 2022
Estimated Study Completion Date :	March 31, 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Dai YH, Yu XJ, Xu HT, Zhuang L, Zhang MS, Zou YM, Fu Q, Qiu H, Yuan XL. Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study). Ther Adv Med Oncol. 2022 Aug 12;14:17588359221118020. doi: 10.1177/17588359221118020. eCollection 2022.

To Top